Rucaparib in combination with nivolumab is currently in clinical development for the treatment of newly diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer, following a response to front-line platinum-based chemotherapy. Epithelial ovarian, fallopian tube, and primary peritoneal cancer are all similar types of ovarian cancer. All three types show signs of pain and swelling in the abdominal area. There are currently no combination treatments approved for the maintenance treatment of newly diagnosed ovarian cancer that includes a poly(ADP-ribose) polymerase (PARP) inhibitor in combination with programmed death-1 (PD-1) receptor inhibitor.
Rucaparib with nivolumab for the maintenance treatment of newly diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer
Rucaparib in combination with nivolumab is currently in clinical development for the treatment of newly diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer, following a response to front-line platinum-based chemotherapy. Epithelial ovarian, fallopian tube, and primary peritoneal cancer are all similar types of ovarian cancer.